Strong order book and revenue growth mask the margin miss that FII won't overlook

The headline number tells only half the story. Cyient's reported PAT grew 5.8% to ₹34.0 Cr, but embedded in that is a ₹18.2 Cr earnout reversal (benefit from the Altek/Eaton Electronics acquisition accounting). Strip it out and normalized PAT reached ₹15.8 Cr — a healthy 25.8% year-over-year gain. The real tension: revenue momentum and order book visibility are genuinely strong, but the EBITDA margin came in at 8.7%, below management's stated 9–10% guidance for FY27. Management blamed deliberate investments in sales, marketing, and product development (100–150 bps drag in Q2), expecting recovery in H2. Investors aren't waiting to believe it — the stock is down 28.64% from its all-time high, FII ownership has collapsed to 0.25%, and the day-1 post-result decline held.

Cyient sits on an all-time record order book of ₹2,810 Cr with a 1.6x book-to-bill ratio, exceeding the full-year 1.5x guidance management set in Q1. Revenue conversion, however, is constrained: management cited material sourcing and supply chain headwinds as the throttle, with an 18–24 month typical delivery cycle. The company is guiding for ₹400–500 Cr in quarterly order conversion, implying the backlog will take 5–7 quarters to clear at current run-rates. Aerospace is 47% of revenue (+62% YoY growth), followed by Industrial (31%, +29%) and Medical/Defense rounding out the mix. This concentration — particularly in cyclical aerospace — is a structural risk, but long-term contracts (Honeywell's 9-year avionics build-to-print deal ramping FY29+) and diversified customer bases within segments provide offsetting hedges.

Book-to-bill upgraded. Prior Q1 guidance was 1.5x full-year; Q2 delivered 1.6x in a single quarter, suggesting near-term order flow remains robust despite supply chain headwinds. Semiconductor capital equipment already generating revenue. Management had signaled this would ramp in FY27–29; it is already flowing in the last two quarters, a positive early indicator. B2S programs advancing with contracts signed. Four programs totaling ~₹1B are moving from pipeline to prototype and testing; some customer contracts are signed. Production and revenue ramp expected FY29–FY30, slightly earlier than the original 'meaningful revenue in 1–18 months' claim from Q1. Sales/marketing and product investment intensity increased. Management added salespeople, a Chief Growth Officer, and bid team resources. This investment is expensed (not capitalized), creating the 100–150 bps Q2 margin drag. Margin guidance moderately missed. Q2 delivered 8.7% vs. 9–10% stated FY27 target — a 120 bps shortfall. Management maintains FY28 will see 'double-digit' EBITDA margins but offered no specific number, creating credibility friction.

Cyient's stock hit an all-time high of ₹1,060.95 but is now trading at ₹757.05 — a 28.64% drawdown. The sell-off accelerated after the result: the stock declined 12.9% on day 1 post-announcement (delivery 38.2%), and that initial move has held. The fundamental story is strong (order book, revenue growth, normalized profit growth), so the price action is a direct indictment of earnings quality and execution risk. FII ownership has collapsed to 0.25% (latest filed quarter, FY27 Q1), down from 2.48% a year ago — a staggering 223 bps outflow. This is not passive rebalancing; it is institutions exiting on the margin miss. DII ownership rose to 29.19% (+252 bps QoQ), and promoters hold steady at 52.11%. Promoter steadiness is reassuring, but the foreign fund exit is a vote of no-confidence on near-term execution. The stock now trades below its 20-day SMA (₹924.97) and 50-day SMA (₹863.45), though above the 200-day (₹531.28). RSI at 36.1 signals neutral/weak momentum. Trading volume is increasing, suggesting accumulation or continued profit-taking — the tape is not yet finding a floor.